<DOC>
	<DOCNO>NCT01038674</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety tolerability drug Anti-IL-20 subject rheumatoid arthritis .</brief_summary>
	<brief_title>Safety Tolerability Anti-IL-20 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Informed consent obtain trialrelated activity A diagnosis rheumatoid arthritis make least 3 month prior screen Active rheumatoid arthritis , characterise DAS28 equal 3.2 Methotrexate treatment ( stable dose , equal 25 mg/week ) least 4 week prior study start ( subject receive stable dos oral corticosteroid , and/or nonsteroidal antiinflammatory drug and/or acetaminophen and/or opioids accord prescribed recommend dos include ) Male subject female subject nonchild bear potential Body mass index ( BMI ) less 18.5 35.0 kg/m2 Subjects chronic inflammatory autoimmune disease rheumatoid arthritis History current inflammatory joint disease rheumatoid arthritis Chronic ongoing infectious disease require systemic antiinfectious treatment within 2 week prior study start Past current malignancy ( judged investigator ) Clinically significant cardiac cardiovascular disease Positive human immunodeficiency virus ( HIV ) , hepatitis tuberculosis Blood donation blood loss 0.45L within 2 month prior study start , longer required local regulation Breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>